Fisher & Paykel Healthcare can’t predict the future

Fisher & Paykel Healthcare can’t predict the future
Chief executive Lewis Gradon told analysts there was a big opportunity ahead but couldn't say when the company would reach it. (Photo: Supplied)
Dan Brunskill
Medical device manufacturer Fisher & Paykel Healthcare is unquestionably in a better position than it was pre-covid, the question everyone is asking is: how much better? It was a question that not even chief executive Lewis Gradon was able to answer when asked by analysts after reporting earnings on Wednesday. The company declined to give earnings guidance for the third straight year, saying it was too hard to predict how much stock customers would want to hold and the possibility of future covid-19 surges.Unable to give guidance,...

More Markets

US CMS recommends 30% increase for Pacific Edge's Cxbladder Triage Plus price
Markets

US CMS recommends 30% increase for Pacific Edge's Cxbladder Triage Plus price

Cancer diagnostics company Pacific Edge has announced that the United States' Centers for Medicare & Medicaid Services (CMS) recommended a final “gapfill” price for its Cxbladder Triage Plus.CMS is proposing a price of US$1,328.32 (NZ$2,241.71), which is about 30% higher than...

Briscoe's bottom line squeezed despite flat first-half sales
Retail

Briscoe's bottom line squeezed despite flat first-half sales

Rod Duke expects full-year profits to come in lower than previously signalled.

ANZ's NZ operation may escape worst of 'Nuno-geddon'
Finance

ANZ's NZ operation may escape worst of 'Nuno-geddon'

ANZ NZ’s performance might be its potential saving grace.

NZX 50 stumbles as Ebos losses mount
Markets Market Close

NZX 50 stumbles as Ebos losses mount

The NZX 50 has erased Monday's gains. 

Gregor Thompson 09 Sep 2025